Treatment response after unusual low dose sorafenib: Diagnosis with perfusion ct and follow-up in a patient with recurrent hepatocellular carcinoma

Journal of Gastrointestinal Cancer

Volumn 43, Issue SUPPL. 1, 2012, Pages

  Sacco, Rodolfo ^a,b   Faggioni, Lorenzo ^a   Bargellini, Irene ^a   Romano, Antonio ^a   Bertini, Marco ^a   Ginanni, Barbara ^a   Battaglia, Valentina ^a   Bertoni, Michele ^a   Bozzi, Elena ^a   Federici, Graziana ^a   Metrangolo, Salvatore ^a   Parisi, Giuseppe ^a   Neri, Emanuele ^a   Sodini, Elisabetta ^a   Tumino, Emanuele ^a   Bresci, Giampaolo ^a   Bartolozzi, Carlo ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CASE REPORT; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; LOW DRUG DOSE; LYMPH NODE METASTASIS; LYMPHADENOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION CT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIODIAGNOSIS; RADIOFREQUENCY ABLATION; RECURRENT CANCER; SYSTEMIC THERAPY; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; COMPUTER ASSISTED TOMOGRAPHY; LIVER NEOPLASMS; PATHOLOGY; PROGNOSIS; RADIOGRAPHY; TUMOR RECURRENCE; ADVANCED CANCER; CANCER SIZE; CANCER STAGING; CHEMOEMBOLIZATION; DRUG INDUCED DISEASE; ECHOGRAPHY; HAND FOOT SKIN REACTION; SCINTISCANNING; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84887403787     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-012-9403-4     Document Type: Article

References (23)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-6.
2. Clavien PA. Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg. 2007;245:843-5.
3. Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011;8:292-301.
4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
5. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
6. Lencioni R. Second interim results of the GIDEON (Global Investigation of Therapeutic DEcisions in HCC and of its treatment with sorafenib) study: Barcelona Clinic Liver Cancer (BCLC) Stage Subgroup Analysis (abstract #6500). In: ESMO-ECCO oncology meeting Stockholm; 2011.
7. Manchen E, Robert C, Porta C. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol. 2011;9:13-23.
8. Sacco R, Bargellini I, Ginanni B, Bozzi E, Altomare E, Battaglia V, et al. Partial response and cardiovascular recovery after sorafenib dose reduction in a multinodular HCC patient. J Gastrointest Cancer. 2011. doi: 10.1007/s12029-011-9328-3.
9. Kim JS. Sorafenib dose ramp up scheme for the treatment of advanced hepatocellular Carcinoma. In: ECCO-ESMO meeting. vol. 6582. Stockholm; 2011.
10. Sacco R. Long term use of sorafenib in clinical practice: what can we learn from clinical practice. Dig Liver Dis. 2010;43(Supp 3).
11. Abbadessa G, Rimassa L, Pressiani T, Carrillo-Infante C, Cucchi E, Santoro A. Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib. World J Gastroenterol. 2011;17:2450-3.
12. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology. 2011;54:2055-63.
13. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60.
14. Marcus CD, Ladam-Marcus V, Cucu C, Bouche O, Lucas L, Hoeffel C. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol. 2009;72:217-38.
15. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-30.
16. Kan Z, Kobayashi S, Phongkitkarun S, Charnsangavej C. Functional CT quantification of tumor perfusion after transhepatic arterial embolization in a rat model. Radiology. 2005;237:144-50.
17. Ng CS, Wang X, Faria SC, Lin E, Charnsangavej C, Tannir NM. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. AJR Am J Roentgenol. 2010;194:166-71.
18. Jiang T, Kambadakone A, Kulkarni NM, Zhu AX, Sahani DV. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol. 2012;47:11-7.
19. Materne R, Van Beers BE, Smith AM, Leconte I, Jamart J, Dehoux JP, et al. Non-invasive quantification of liver perfusion with dynamic computed tomography and a dual-input one-compartmental model. Clin Sci (Lond). 2000;99:517-25.
20. Sahani DV, Holalkere NS, Mueller PR, Zhu AX. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue - initial experience. Radiology. 2007;243:736-43.
21. Oto A, Tamm EP, Szklaruk J. Multidetector row CT of the liver. Radiol Clin North Am. 2005;43:827-48.
22. Pandharipande PV, Krinsky GA, Rusinek H, Lee VS. Perfusion imaging of the liver: current challenges and future goals. Radiology. 2005;234:661-73.
23. Jelic S. Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:41-5.